Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Liquidia Corporation (LT4.F)

Compare
13.20
+0.01
+(0.08%)
At close: March 14 at 5:56:07 PM GMT+1
Loading Chart for LT4.F
  • Previous Close 13.19
  • Open 12.80
  • Bid --
  • Ask --
  • Day's Range 12.80 - 13.20
  • 52 Week Range 7.93 - 15.70
  • Volume 100
  • Avg. Volume 146
  • Market Cap (intraday) 1.125B
  • Beta (5Y Monthly) 0.07
  • PE Ratio (TTM) --
  • EPS (TTM) -1.49
  • Earnings Date Mar 19, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

www.liquidia.com

145

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LT4.F

View More

Performance Overview: LT4.F

Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 .

YTD Return

LT4.F
20.11%
S&P 500
4.13%

1-Year Return

LT4.F
0.75%
S&P 500
9.48%

3-Year Return

LT4.F
134.04%
S&P 500
35.13%

5-Year Return

LT4.F
328.57%
S&P 500
108.00%

Compare To: LT4.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LT4.F

View More

Valuation Measures

As of 3/14/2025
  • Market Cap

    1.13B

  • Enterprise Value

    939.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    67.88

  • Price/Book (mrq)

    10.97

  • Enterprise Value/Revenue

    65.32

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.28%

  • Return on Equity (ttm)

    -150.73%

  • Revenue (ttm)

    15.61M

  • Net Income Avi to Common (ttm)

    -119.47M

  • Diluted EPS (ttm)

    -1.49

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    204.37M

  • Total Debt/Equity (mrq)

    104.81%

  • Levered Free Cash Flow (ttm)

    -53.61M

Research Analysis: LT4.F

View More

People Also Watch